The clinical case for banking autologous adipose tissue rests on a research pipeline, and that pipeline is best understood from primary sources rather than summaries. As of 2026, active trials are studying adipose-derived mesenchymal stem cells across several condition categories, from neurodegenerative disease to musculoskeletal and inflammatory conditions. What follows is a physician reference to the active programs, with NCT numbers, phases, sponsors, and current status drawn from ClinicalTrials.gov, framed so that the banking connection stays a matter of optionality rather than a promise of access.
TLDR: Active 2026 trials using adipose-derived MSCs include Mayo Clinic’s intrathecal autologous program for multiple system atrophy (NCT05167721, Phase 2) and for ALS (NCT03268603, Phase 2), and Hope Biosciences’ autologous program for chronic traumatic brain injury (NCT05951777, Phase 2). A Danish allogeneic adipose program for heart failure (NCT03092284, Phase 2) is completed. Most adipose programs are autologous and early-to-mid phase. Patients with banked autologous tissue are positioned to explore autologous-trial eligibility, which is trial-specific and cannot be assured at the time of banking. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for the conditions discussed in this article. The trials referenced here are investigational. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
A reference like this is only as good as its sourcing, and trial status changes month to month, so every entry below should be re-verified against the live ClinicalTrials.gov record before a physician relies on it for a referral. The value of banking, viewed through this pipeline, is optionality: a documented autologous sample that may become relevant if and when a patient and physician determine that a trial or authorized pathway fits. That is the honest frame, and it is the only one that holds.
Why the Pipeline Matters for Banking Decisions
The clinical utility of banked adipose tissue is tied to the pipeline of trials and eventual therapies that may use autologous adipose-derived cells. The banking decision is, at its core, a decision about optionality. A patient who banks tissue today holds a documented, accessible sample that may become clinically actionable as trials advance or as authorized or expanded-access pathways develop. That is not a guarantee of access to any therapy, and it should never be presented as one. What banking does is keep a door open that cannot be opened retroactively, because autologous approaches require the patient’s own tissue to have been collected and preserved. Understanding what trial phases actually mean is itself worth grounding, which the explainer on clinical trial phases covers.
Active Trial Reference Table
| Condition | NCT | Phase | Sponsor | Tissue type | Status | Notes |
|---|---|---|---|---|---|---|
| Multiple system atrophy | NCT05167721 | Phase 2 | Mayo Clinic | Autologous adipose-derived MSC | Active, not recruiting | Intrathecal; est. completion 2026 |
| Chronic traumatic brain injury | NCT05951777 | Phase 2 | Hope Biosciences | Autologous adipose-derived MSC | Recruiting | Vs. saline placebo; est. completion 2026 |
| Amyotrophic lateral sclerosis | NCT03268603 | Phase 2 | Mayo Clinic | Autologous adipose-derived MSC | Active, not recruiting | Intrathecal administration |
| Heart failure | NCT03092284 | Phase 2 | Investigator-sponsored (Denmark) | Allogeneic adipose-derived MSC | Completed | Allogeneic, not autologous |
| Knee osteoarthritis | NCT07339111 | Phase 3 | Medipost | Allogeneic umbilical-cord-blood MSC | US IND cleared 2026 | NOT adipose; included as pipeline context only |
Two of those rows carry deliberate flags. The heart-failure program is allogeneic and completed, so it is pipeline history rather than an autologous-banking opportunity. The knee osteoarthritis Phase 3 is an umbilical-cord-blood product, not an adipose therapy at all; it is listed only to show that musculoskeletal cell therapy is reaching late-stage trials, not because banked adipose tissue would be relevant to it. Verify every cell at the live record before acting.
Condition-by-Condition Summary
Multiple system atrophy (NCT05167721)
Mayo Clinic’s Phase 2 trial studies autologous adipose-derived MSCs administered intrathecally in MSA, a rare and rapidly progressive neurodegenerative disease with no disease-modifying therapy. Adipose-derived cells are the chosen source in part because they can be obtained autologously through a minor procedure and because MSCs are being studied for neuroprotective and immunomodulatory effects relevant to neurodegeneration. As a Phase 2 program, it is designed to assess preliminary efficacy and safety, not to establish standard of care, and there is no FDA-approved MSC therapy for MSA. For a physician whose MSA patient has banked tissue, the relevance is contextual: the existence of an autologous program means a documented sample could matter, but eligibility is trial-specific. This trial is examined in its own dedicated breakdown.
Chronic traumatic brain injury (NCT05951777)
Hope Biosciences runs a Phase 2 trial of its autologous adipose-derived MSCs (HB-adMSCs) against a saline placebo in chronic TBI, a condition with no approved disease-modifying or regenerative therapy. The autologous design is notable because the banking step is built into the company’s model. Phase 2 status again means preliminary efficacy and safety, not established benefit. The forward-looking relevance for a TBI patient with banked tissue is the same optionality argument, held to the same limits.
Amyotrophic lateral sclerosis (NCT03268603)
Mayo Clinic’s Phase 2 ALS program also uses intrathecal autologous adipose-derived MSCs. ALS, like MSA, is a progressive neurodegenerative disease where the rationale for MSC study rests on possible neuroprotective and immunomodulatory mechanisms. The evidence remains investigational, and the trial is active but not recruiting, which is exactly the kind of status that should be re-checked before any referral.
Heart failure (NCT03092284)
This Danish Phase 2 program studied an allogeneic adipose-derived cell product and is completed. It is included for pipeline completeness, but because it is allogeneic rather than autologous, it does not connect to the autologous-banking rationale, and its completed status means it is not an enrollment opportunity.
The Banking-to-Trial Readiness Framework
What does a patient need to potentially be eligible for an autologous adipose MSC trial? Banked autologous tissue of adequate quality and quantity, processed under a documented protocol; complete chain-of-custody documentation from harvest to storage; processing at an FDA-registered, cGMP-compliant facility; and a clinical profile that matches a given trial’s inclusion and exclusion criteria, which is trial-specific and cannot be determined at the time of banking. Communication between the banking physician and a trial’s principal investigator is often the practical bridge. A critical caveat that the Hope Biosciences model makes concrete: each trial has its own cell-preparation and manufacturing requirements, so banked tissue from a third-party facility does not automatically qualify for use in a given trial. This is a planning framework, not a guarantee of eligibility.
Banking-to-Trial Readiness Checklist
- Autologous adipose tissue banked and confirmed in cryostorage.
- Chain-of-custody documentation complete from harvest to storage.
- Processing facility FDA-registered and cGMP-compliant.
- Volume banked sufficient for likely applications (confirm with the processing partner).
- Patient’s condition documented and relevant to one or more active pipelines.
- Relevant active trials reviewed at ClinicalTrials.gov.
- Expanded access options reviewed if the patient may not qualify for active enrollment.
Frequently Asked Questions
Does banking tissue get a patient into a trial?
No. Banking preserves an autologous sample, which is a prerequisite for any autologous approach, but trial eligibility is determined by each trial’s own criteria, and each trial has its own manufacturing requirements that third-party banked tissue may not meet. Banking keeps an option open; it does not confer access.
Are all the trials in the table adipose-derived and autologous?
No, and the distinction matters. The MSA, TBI, and ALS programs are autologous adipose-derived. The heart-failure program is allogeneic and completed. The knee osteoarthritis Phase 3 is an umbilical-cord-blood product, not adipose at all, and is listed only as pipeline context.
How current is this table?
It reflects the ClinicalTrials.gov record as of writing, but trial status changes frequently. Verify each entry at the live record before relying on it for a referral.
Key Takeaways
The active adipose-MSC pipeline in 2026 is real but mostly early-to-mid phase and concentrated in autologous neurodegenerative programs: Mayo Clinic’s MSA and ALS trials and Hope Biosciences’ TBI trial are the clearest autologous examples, all Phase 2. Some programs often grouped with adipose work do not actually belong there, the heart-failure trial is allogeneic and completed, and the prominent knee osteoarthritis Phase 3 is an umbilical-cord-blood product, so a physician reading any roundup should check the cell source and status rather than assume. The banking rationale that follows from this pipeline is optionality, a documented autologous sample that may become relevant, bounded hard by the fact that trial eligibility and trial-specific manufacturing requirements cannot be assured in advance. Banking is a preservation decision separate from therapy, with no guarantee of future benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Physicians evaluating how banked tissue fits a patient’s long-term options can contact Save My Fat to discuss the preservation side.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
